( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
276	軟骨無形成症	46

276. 軟骨無形成症

臨床試験数 : 46 / 薬物数 : 29 - (DrugBank : 6) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 30

diseases per page:

Showing 1 to 10 of 46 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-001855-15-ES (EUCTR)	02/02/2022	15/09/2021	A study to evaluate long-term Infigratinib in children with Achondroplasia	Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosin ...	Achondroplasia in Children <br>MedDRA version: 20.0;Level: LLT;Classification code 10000452;Term: Ac ...	Product Name: Infigratinib<br>Product Code: BGJ398 (also known as BBP-831)<br>INN or Proposed INN: I ...	QED Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			<an>br>Female: yes Male: yes	280	Phase 2	France;United States;Canada;Spain;Australia;United Kingdom
2	NCT05246033 (ClinicalTrials.gov)	January 5, 2022	9/2/2022	A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous D ...	ACcomplisH China: A Phase 2, Multicenter, Randomized, Placebo-controlled, Dose Escalation Trial Eval ...	Achondroplasia	Drug: TransCon CNP;Drug: Placebo for TransCon CNP	Ascendis Pharma A/S	NULL	Recruiting	2 Years	10 Years	All	64	Phase 2	China
3	EUCTR2021-003149-39-ES (EUCTR)	14/12/2021	17/09/2021	A PHASE 2 OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS ...	A PHASE 2 OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS ...	Achondroplasia <br>MedDRA version: 20.0;Level: LLT;Classification code 10000452;Term: Achondroplasia ...	Product Name: Recifercept (proposed INN)<br>Product Code: PF-07256472<br>INN or Proposed INN: Recife ...	Pfizer Inc.	NULL	Authorised-recruitment may be ongoing or finished			<an>br>Female: yes Male: yes	63	Phase 2	Portugal;United States;Belgium;Spain;Denmark;Australia;Italy;Japan
4	NCT05116046 (ClinicalTrials.gov)	December 7, 2021	18/10/2021	Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept i ...	A PHASE 2 OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS ...	Achondroplasia	Biological: Recifercept	Pfizer	NULL	Not yet recruiting	15 Months	12 Years	All	63	Phase 2	NULL
5	NCT05145010 (ClinicalTrials.gov)	December 6, 2021	22/11/2021	Extension Study of Infigratinib in Children With Achondroplasia (ACH)	Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosin ...	Achondroplasia	Drug: Infigratinib	QED Therapeutics, Inc.	NULL	Recruiting	3 Years	18 Years	All	280	Phase 2	Australia;United Kingdom
6	EUCTR2020-001189-13-PT (EUCTR)	26/02/2021	29/09/2020	Phase 2 study of safety, tolerability, PK and efficacy of recifercept in achondroplasia	A PHASE 2 MULTIPLE DOSE, RANDOMIZED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND ...	Achondroplasia <br>MedDRA version: 20.0;Level: LLT;Classification code 10000452;Term: Achondroplasia ...	Product Name: Recifercept (proposed INN)<br>Product Code: PF-07256472<br>INN or Proposed INN: Recife ...	Pfizer Inc.	NULL	Authorised-recruitment may be ongoing or finished			<an>br>Female: yes Male: yes	63	Phase 2	United States;Portugal;Spain;Belgium;Denmark;Australia;United Kingdom;Italy;Japan
7	EUCTR2019-002754-22-PT (EUCTR)	05/02/2021	18/06/2020	A Phase 2 study to evaluate the safety, efficacy and pharmacokinetics of TransCon CNP in prepubertal ...	ACcomplisH: A Phase 2, multicenter, double-blind, randomized, placebo-controlled, dose escalation tr ...	Achondroplasia (ACH) in prepubertal children <br>MedDRA version: 20.0;Level: LLT;Classification code ...	Product Name: TransCon CNP 3.9 mg CNP-38/vial<br>Product Code: TransCon CNP<br>INN or Proposed INN: ...	Ascendis Pharma Growth Disorders A/S	NULL	Authorised-recruitment may be ongoing or finished			<an>br>Female: yes Male: yes	60	Phase 2	United States;Portugal;Canada;Spain;Ireland;Denmark;Austria;Australia;Germany;United Kingdom;Switzer ...
8	EUCTR2020-001189-13-IT (EUCTR)	05/02/2021	15/06/2021	Phase 2 study of safety, tolerability, PK and efficacy of recifercept in achondroplasia	A PHASE 2 MULTIPLE DOSE, RANDOMIZED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND E ...	Achondroplasia <br>MedDRA version: 20.0;Level: LLT;Classification code 10000452;Term: Achondroplasia ...	Product Name: Recifercept<br>Product Code: [PF-07256472]<br>INN or Proposed INN: Recifercept	PFIZER INC	NULL	Authorised-recruitment may be ongoing or finished			<an>br>Female: yes Male: yes	63	Phase 2	Portugal;United States;Spain;Belgium;Denmark;Australia;United Kingdom;Japan;Italy
9	EUCTR2020-001189-13-DK (EUCTR)	22/12/2020	07/10/2020	Phase 2 study of safety, tolerability, PK and efficacy of recifercept in achondroplasia	A PHASE 2 MULTIPLE DOSE, RANDOMIZED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND ...	Achondroplasia <br>MedDRA version: 20.0;Level: LLT;Classification code 10000452;Term: Achondroplasia ...	Product Name: Recifercept (proposed INN)<br>Product Code: PF-07256472<br>INN or Proposed INN: Recife ...	Pfizer Inc., 235 East 42nd Street, New York, NY 10017	NULL	Authorised-recruitment may be ongoing or finished			<an>br>Female: yes Male: yes	63	Phase 2	Portugal;United States;Spain;Belgium;Australia;Denmark;Italy;Japan
10	NCT04638153 (ClinicalTrials.gov)	December 2, 2020	15/9/2020	A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia	A PHASE 2 MULTIPLE DOSE, RANDOMIZED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND E ...	Achondroplasia	Biological: Recifercept	Pfizer	NULL	Recruiting	3 Months	10 Years	All	63	Phase 2	United States;Australia;Belgium;Denmark;Italy;Portugal;Spain

First Previous1 2 3 4 5Next Last